Patent SG-11201809857T-A (SG)
Title: Anti-CTLA-4 Antibodies
Inventor: WANG CHENG-I
IPC: C07K16/28
Filed: 2017-04-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 IIIIIIIIIIIIIIIIIII101110111101111011111111011111111111011111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194265 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (SG). YEO, Siok Ping; c/o Agency for Science Technology C07K 16/28 (2006.01) and Research, 8A Biomedical Grove 03-00, 138648 (SG). (21) International Application Number: (74) Agent: CLEGG, Richard et al.; Mewburn Ellis LLP, City PCT/EP2017/058956 Tower, 40 Basinghall Street, London Greater London EC2V (22) International Filing Date: 5DE (GB). 13 April 2017 (13.04.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 10201603721T 10 May 2016 (10.05.2016) SG KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, #20-10, Connexis 138632 (SG). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant or LS only): CLEGG, Richard Ian [GB/GB]; City Tower, 40 Basinghall Street, London Greater London (84) Designated States (unless otherwise indicated, for every EC2V 5DE (GB). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: WANG, Cheng-I; c/o Agency for Science UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Technology and Research, 8A Biomedical Grove 03-00, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 138648 (SG). NGOH, Eve; c/o Agency for Science Tech- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = — = nology and Research, 8A Biomedical Grove 03-00, 138648 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: Anti-CTLA-4 Antibodies = 2C8 clone DIQLTQSPSSVSASVGDRVTITCRATQG ISSWLAWYQQKPGKAPKLLIYAASSLQS = GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQANTLPLFTFGPGTKVDIK (SEQ ID NO: 1) = _ LC-CDR1: RATQGISSWLA (SEQ ID NO:5) = LC-CDR2: AASSLQS (SEQ ID NO:6) = LC-CDR3: QQANTLPLFT (SEQ ID NO:7) — = = = 2C8 gl clone = DIQMTQSPSSVSASVGDRVTITCRATQGISSWLAWYQQKPGKAPKLLIYAASSLQS = GVPSRFSGSGSGTDFTLTISSLOPEDFATYYCQQANTLPLFTFGPGTKVDIK (SEQ ID NO: 2) 1-1 LC-CDR1: RATQGISSWLA (SEQ ID NO:5) LC-CDR2: AASSLQS (SEQ ID NO:6) kr) LC-CDR3: QQANTLPLFT (SEQ ID NO:7) N 71' 0\ Il IN Figure 1 1-1 <= (57) : Anti-CTLA-4antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and meth- \" ods using the same. [Continued on next page] WO 2017/194265 Al MIDEDIM01101 DIDIRMEM1111111111111111111111111H1101111111111111111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))